Source: medigence Blog

medigence Blog CAR-T Therapy: Revolutionizing Treatment for Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma (NHL) is the most common form of lymphatic cancer, affecting thousands of people globally. In patients with relapsed or refractory Non-Hodgkin Lymphoma, The post CAR-T Therapy: Revolutionizing Treatment for Non-Hodgkin Lymphoma appeared first on MediGence.

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Amit Bansal's photo - Co-Founder & CEO of MediGence

Co-Founder & CEO

Amit Bansal

CEO Approval Rating

90/100

Read more